Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic reviewDiabetes, obesity & metabolism, 2018-02, Vol.20 (2), p.427ISSN: 1463-1326 ;EISSN: 1463-1326 ;DOI: 10.1111/dom.13088Digital Resources/Online E-Resources |
|
2 |
Material Type: Article
|
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetesDiabetes, obesity & metabolism, 2015-12, Vol.17 (12), p.1180-11932015 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. ;2015 John Wiley & Sons Ltd ;2015. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1462-8902 ;EISSN: 1463-1326 ;DOI: 10.1111/dom.12572 ;PMID: 26343814 ;CODEN: DOMEF6Full text available |
|
3 |
Material Type: Article
|
Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT studyDiabetes, obesity & metabolism, 2016-09, Vol.18 (9), p.907-9152016 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. ;2016 John Wiley & Sons Ltd ;2016. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1462-8902 ;ISSN: 1463-1326 ;EISSN: 1463-1326 ;DOI: 10.1111/dom.12689 ;PMID: 27161418 ;CODEN: DOMEF6Full text available |
|
4 |
Material Type: Article
|
Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetesDiabetes, obesity & metabolism, 2012-09, Vol.14 (9), p.859-8642012 Blackwell Publishing Ltd ;2012 Blackwell Publishing Ltd. ;ISSN: 1462-8902 ;EISSN: 1463-1326 ;DOI: 10.1111/j.1463-1326.2012.01627.x ;PMID: 22594461Full text available |
|
5 |
Material Type: Article
|
Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonistsDiabetes, obesity & metabolism, 2016-04, Vol.18 (4), p.317-3322015 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. ;2016 John Wiley & Sons Ltd ;ISSN: 1462-8902 ;EISSN: 1463-1326 ;DOI: 10.1111/dom.12596 ;PMID: 26511102 ;CODEN: DOMEF6Full text available |
|
6 |
Material Type: Article
|
New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)Diabetes, obesity & metabolism, 2015-04, Vol.17 (4), p.386-3942015 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. ;2015 John Wiley & Sons Ltd ;2015. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2015 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. 2015 ;ISSN: 1462-8902 ;EISSN: 1463-1326 ;DOI: 10.1111/dom.12438 ;PMID: 25641260 ;CODEN: DOMEF6Full text available |
|
7 |
Material Type: Article
|
Cancer Risk Associated with Use of Metformin and Sulfonylurea in Type 2 Diabetes: A Meta‐AnalysisThe oncologist (Dayton, Ohio), 2012, Vol.17 (6), p.813-822 [Peer Reviewed Journal]2012 AlphaMed Press ;AlphaMed Press 2012 ;ISSN: 1083-7159 ;EISSN: 1549-490X ;DOI: 10.1634/theoncologist.2011-0462 ;PMID: 22643536Full text available |
|
8 |
Material Type: Article
|
Diabetes and Cancer: A Consensus ReportCA: a cancer journal for clinicians, 2010-07, Vol.60 (4), p.207-221 [Peer Reviewed Journal]Copyright © 2010 American Cancer Society, Inc. ;(c) 2010 American Cancer Society, Inc. ;Copyright Lippincott Williams & Wilkins Jul/Aug 2010 ;ISSN: 0007-9235 ;EISSN: 1542-4863 ;DOI: 10.3322/caac.20078 ;PMID: 20554718 ;CODEN: CAMCAMFull text available |
|
9 |
Material Type: Article
|
Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 PatientsJournal of the American Heart Association, 2017-05, Vol.6 (6) [Peer Reviewed Journal]2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. ;ISSN: 2047-9980 ;EISSN: 2047-9980 ;DOI: 10.1161/JAHA.116.004007 ;PMID: 28546454Full text available |
|
10 |
Material Type: Article
|
Pharmacokinetic and pharmacodynamic interaction between DWP16001, an sodium–glucose cotransporter 2 inhibitor and metformin in healthy subjectsBritish journal of clinical pharmacology, 2023-04, Vol.89 (4), p.1462-1470 [Peer Reviewed Journal]2022 British Pharmacological Society. ;ISSN: 0306-5251 ;EISSN: 1365-2125 ;DOI: 10.1111/bcp.15613 ;PMID: 36422809Full text available |
|
11 |
Material Type: Article
|
MEDI0382, a GLP‐1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single‐dose, healthy‐subject, randomized, Phase 1 studyBritish journal of clinical pharmacology, 2018-10, Vol.84 (10), p.2325-2335 [Peer Reviewed Journal]2018 The British Pharmacological Society ;2018 The British Pharmacological Society. ;ISSN: 0306-5251 ;EISSN: 1365-2125 ;DOI: 10.1111/bcp.13688 ;PMID: 29926478Full text available |
|
12 |
Material Type: Article
|
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trialInternational journal of clinical practice (Esher), 2013-12, Vol.67 (12), p.1267-1282 [Peer Reviewed Journal]2013 The Authors International Journal of Clinical Practice Published by John Wiley & Sons Ltd ;2013 The Authors International Journal of Clinical Practice Published by John Wiley & Sons Ltd. ;Copyright © 2013 John Wiley & Sons Ltd ;2013 The Authors International Journal of Clinical Practice Published by John Wiley & Sons Ltd 2013 ;ISSN: 1368-5031 ;EISSN: 1742-1241 ;DOI: 10.1111/ijcp.12322 ;PMID: 24118688Full text available |
|
13 |
Material Type: Article
|
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazoneDiabetes, obesity & metabolism, 2014-05, Vol.16 (5), p.467-4772014 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. ;2014. This article is published under http://creativecommons.org/licenses/by-nc-nd/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2014 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. 2014 ;ISSN: 1462-8902 ;EISSN: 1463-1326 ;DOI: 10.1111/dom.12273 ;PMID: 24528605 ;CODEN: DOMEF6Full text available |
|
14 |
Material Type: Article
|
LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled TrialClinical pharmacology and therapeutics, 2012-08, Vol.92 (2), p.158-169 [Peer Reviewed Journal]2012 American Society for Clinical Pharmacology and Therapeutics ;2015 INIST-CNRS ;Copyright © 2012 American Society of Clinical Pharmacology and Therapeutics 2012 American Society of Clinical Pharmacology and Therapeutics ;ISSN: 0009-9236 ;EISSN: 1532-6535 ;DOI: 10.1038/clpt.2012.58 ;PMID: 22739142 ;CODEN: CLPTATFull text available |
|
15 |
Material Type: Article
|
Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosisBritish journal of clinical pharmacology, 2022-01, Vol.88 (1), p.311-322 [Peer Reviewed Journal]2021 The Authors. published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. ;2021 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. ;ISSN: 0306-5251 ;EISSN: 1365-2125 ;DOI: 10.1111/bcp.14970 ;PMID: 34198358Full text available |
|
16 |
Material Type: Article
|
Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with Type 2 diabetesDiabetic medicine, 2016-04, Vol.33 (4), p.511-514 [Peer Reviewed Journal]2016 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK. ;2015 Diabetes UK. ;ISSN: 0742-3071 ;EISSN: 1464-5491 ;DOI: 10.1111/dme.13040 ;PMID: 26605869 ;CODEN: DIMEEVFull text available |
|
17 |
Material Type: Article
|
Metformin in pregnancy: a re‐examination of its safetyThe Journal of physiology, 2022-02, Vol.600 (4), p.705-706 [Peer Reviewed Journal]2021 The Authors. The Journal of Physiology © 2021 The Physiological Society ;Journal compilation © 2022 The Physiological Society ;ISSN: 0022-3751 ;EISSN: 1469-7793 ;DOI: 10.1113/JP282324 ;PMID: 34762307Full text available |
|
18 |
Material Type: Article
|
Albiglutide in patients with type 2 diabetes and heart failure: a post‐hoc analysis from Harmony OutcomesEuropean journal of heart failure, 2022-10, Vol.24 (10), p.1792-1801 [Peer Reviewed Journal]Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 1388-9842 ;EISSN: 1879-0844 ;DOI: 10.1002/ejhf.2660 ;PMID: 36053803Digital Resources/Online E-Resources |
|
19 |
Material Type: Article
|
Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factorsJournal of diabetes investigation, 2016-03, Vol.7 (2), p.135-138 [Peer Reviewed Journal]2015 The Authors. Journal of Diabetes Investigation published by Asian Association of the Study of Diabetes (AASD) and Wiley Publishing Asia Pty Ltd ;2016. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 2040-1116 ;EISSN: 2040-1124 ;DOI: 10.1111/jdi.12401 ;PMID: 27042263Full text available |
|
20 |
Material Type: Article
|
Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trialDiabetes, obesity & metabolism, 2021-03, Vol.23 (3), p.800-810Attribution - NonCommercial - NoDerivatives ;ISSN: 1462-8902 ;EISSN: 1463-1326 ;DOI: 10.1111/dom.14285Digital Resources/Online E-Resources |